rss
J Clin Pathol 2002;55:180-183
  • Review

New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders

  1. E Matutes
  1. Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK
  1. Correspondence to:
 Dr E Matutes, Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK;
 estella{at}icr.ac.uk
  • Accepted 14 September 2001

Abstract

Advances in flow cytometry techniques and the availability of monoclonal antibodies that detect key functional molecules on lymphocytes have contributed greatly to a more precise diagnosis of the chronic lymphoproliferative disorders. In addition to the diagnostic value, the expression of certain markers such as p53 or CD38 provides relevant prognostic information to the clinician. Beyond their diagnostic and prognostic value, immunological markers play a major role in the detection of minimal residual disease, enabling the clinician to estimate more accurately the response to chemotherapy. Those monoclonal antibodies that are relevant to the characterisation of the chronic lymphoproliferative disorders and that could be incorporated in a routine practice are discussed.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.